Documentos relacionados

1. Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.
2. Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE).
3. Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Hungary.
4. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV.
5. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV.
6. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.
7. Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.
8. Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
9. Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase.
10. Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens.